Oppenheimer Boosts Chemed (CHE) Price Target to $275.00

Chemed (NYSE:CHE) had its target price upped by Oppenheimer from $270.00 to $275.00 in a research note issued to investors on Friday. The brokerage currently has an outperform rating on the stock.

Other equities research analysts have also issued research reports about the company. TheStreet raised Chemed from a c+ rating to an a- rating in a research report on Friday, October 27th. Zacks Investment Research raised Chemed from a hold rating to a buy rating and set a $251.00 price target on the stock in a research report on Thursday, November 2nd. Royal Bank of Canada reaffirmed a hold rating and issued a $258.00 price target on shares of Chemed in a research report on Friday. ValuEngine lowered Chemed from a buy rating to a hold rating in a research report on Friday, December 1st. Finally, KeyCorp reaffirmed a hold rating on shares of Chemed in a research report on Friday, October 27th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Chemed currently has a consensus rating of Hold and a consensus target price of $261.33.

Shares of Chemed (NYSE CHE) opened at $254.56 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.88. The stock has a market capitalization of $4,064.30, a PE ratio of 28.73 and a beta of 1.13. Chemed has a 12-month low of $170.69 and a 12-month high of $275.83.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Wednesday, February 14th. The company reported $2.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.05. The company had revenue of $428.35 million for the quarter, compared to analyst estimates of $423.83 million. Chemed had a return on equity of 30.04% and a net margin of 5.89%. Chemed’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.10 EPS.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 19th. Stockholders of record on Monday, February 26th will be issued a $0.28 dividend. The ex-dividend date is Friday, February 23rd. This represents a $1.12 dividend on an annualized basis and a dividend yield of 0.44%. Chemed’s payout ratio is currently 19.28%.

In other news, VP Naomi C. Dallob sold 950 shares of the stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $240.38, for a total value of $228,361.00. Following the transaction, the vice president now owns 9,747 shares in the company, valued at approximately $2,342,983.86. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Michael D. Witzeman sold 1,000 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $250.00, for a total value of $250,000.00. Following the completion of the transaction, the vice president now owns 3,334 shares in the company, valued at approximately $833,500. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,950 shares of company stock worth $3,370,681. Company insiders own 4.90% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC purchased a new position in shares of Chemed in the 4th quarter valued at about $1,738,000. Metropolitan Life Insurance Co. NY purchased a new position in shares of Chemed in the 4th quarter valued at about $1,208,000. Vident Investment Advisory LLC increased its holdings in shares of Chemed by 6.4% in the 4th quarter. Vident Investment Advisory LLC now owns 13,482 shares of the company’s stock valued at $3,276,000 after acquiring an additional 814 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Chemed in the 4th quarter valued at about $1,208,000. Finally, Clark Capital Management Group Inc. increased its holdings in shares of Chemed by 7.4% in the 4th quarter. Clark Capital Management Group Inc. now owns 9,757 shares of the company’s stock valued at $2,371,000 after acquiring an additional 675 shares during the last quarter. Institutional investors and hedge funds own 96.16% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Oppenheimer Boosts Chemed (CHE) Price Target to $275.00” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/02/19/oppenheimer-boosts-chemed-che-price-target-to-275-00.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Oppenheimer Boosts Chemed (CHE) Price Target to $275.00

Chemed (NYSE:CHE) had its price target raised by Oppenheimer from $270.00 to $275.00 in a research note issued to investors on Friday. The firm currently has an outperform rating on the stock.

Several other equities analysts have also commented on CHE. Royal Bank of Canada reaffirmed a hold rating and issued a $258.00 price target on shares of Chemed in a research note on Friday. TheStreet raised Chemed from a c+ rating to an a- rating in a research note on Friday, October 27th. KeyCorp reaffirmed a hold rating on shares of Chemed in a research note on Friday, October 27th. ValuEngine lowered Chemed from a buy rating to a hold rating in a research note on Friday, December 1st. Finally, Zacks Investment Research raised Chemed from a hold rating to a buy rating and set a $251.00 price target on the stock in a research note on Thursday, November 2nd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $261.33.

Chemed (NYSE CHE) opened at $254.56 on Friday. Chemed has a 12 month low of $170.69 and a 12 month high of $275.83. The company has a market capitalization of $4,064.30, a price-to-earnings ratio of 28.73 and a beta of 1.13. The company has a quick ratio of 0.88, a current ratio of 0.91 and a debt-to-equity ratio of 0.17.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Wednesday, February 14th. The company reported $2.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.05. Chemed had a return on equity of 30.04% and a net margin of 5.89%. The business had revenue of $428.35 million for the quarter, compared to analyst estimates of $423.83 million. During the same quarter in the prior year, the company posted $2.10 EPS. The company’s quarterly revenue was up 6.2% on a year-over-year basis.

The company also recently announced a quarterly dividend, which will be paid on Monday, March 19th. Investors of record on Monday, February 26th will be paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Friday, February 23rd. Chemed’s payout ratio is 19.28%.

In related news, VP Naomi C. Dallob sold 950 shares of the stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $240.38, for a total transaction of $228,361.00. Following the transaction, the vice president now owns 9,747 shares of the company’s stock, valued at approximately $2,342,983.86. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Michael D. Witzeman sold 1,000 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $250.00, for a total value of $250,000.00. Following the transaction, the vice president now directly owns 3,334 shares in the company, valued at approximately $833,500. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,950 shares of company stock worth $3,370,681. 4.90% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. IFP Advisors Inc lifted its stake in Chemed by 1,504.5% during the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after acquiring an additional 662 shares in the last quarter. MCF Advisors LLC acquired a new position in Chemed during the 3rd quarter worth about $152,000. Hengehold Capital Management LLC acquired a new position in Chemed during the 4th quarter worth about $203,000. Tocqueville Asset Management L.P. acquired a new position in Chemed during the 4th quarter worth about $205,000. Finally, Magnetar Financial LLC acquired a new position in Chemed during the 3rd quarter worth about $207,000. 96.16% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/02/19/oppenheimer-boosts-chemed-che-price-target-to-275-00.html.

Chemed Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply